Rxivist logo

Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-cell lymphoma therapy

By Senlian Hong, Chenhua Yu, Peng Wang, Yujie Shi, Bo Cheng, Mingkuan Chen, Digantkumar G. Chapla, Natalie Reigh, Yoshiki Narimatsu, Xing Chen, Henrik Clausen, Kelly W. Moremen, Matthew Scott Macauley, James C. Paulson, Peng Wu

Posted 25 Mar 2020
bioRxiv DOI: 10.1101/2020.03.23.004325

CD22, a member of Siglec family of sialic acid binding proteins, has restricted expression on B cells. Antibody-based agents targeting CD22 or CD20 (RituxanTM) on B lymphoma and leukemia cells exhibit clinical efficacy for treating these malignancies, but also attack normal B cells leading to immune deficiency. Here, we report a chemoenzymatic glycocalyx editing strategy to introduce high-affinity and specific CD22 ligands onto NK-92MI and cytokine-induced killer (CIK) cells to achieve tumor-specific CD22 targeting. These CD22-ligand modified cells exhibited significantly enhanced tumor cell binding and killing in vitro without harming healthy B cells. For effective lymphoma cell killing in vivo we further functionalized CD22 ligand-modified NK-92MI cells with the E-selectin ligand sialyl Lewis X to promote trafficking to bone marrow. The cells containing the ligands of both CD22 and selectins resulted in the efficient suppression of B lymphoma in a xenograft model. Our results suggest that NK cells modified with glycan ligands to CD22 and selectins promote both targeted killing of B lymphoma cells and improved trafficking to sites where the cancer cells reside, respectively.

Download data

  • Downloaded 5,859 times
  • Download rankings, all-time:
    • Site-wide: 2,070
    • In bioengineering: 15
  • Year to date:
    • Site-wide: 3,505
  • Since beginning of last month:
    • Site-wide: 16,525

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide